ENTPD1 and cancer: Altogether, these studies indicate that blocking Ado formation through targeting CD39 is a promising strategy in cancer therapy not only for boosting the antitumor immune response (immunotherapy) but also for blocking tumor angiogenesis (antiangiogenic therapy).